Counseling Patients With Chronic Hepatitis C Virus Infection

Debika Bhattacharyya, MD, MSc
Assistant Professor of Medicine
University of California, Los Angeles

Recorded on May 24, 2013
Dr Bhattacharya has reported the following financial relationships with commercial firms:

- Research support from: Vertex Pharmaceuticals, Inc
Outline

- Over-the-counter and prescription medications
- Alcohol and cannabis
- Diet and modifying obesity
- Complementary and alternative medicines
Over-the-Counter and Prescription Medications
Over-the-Counter and Prescription Medications

- Acetaminophen
- Nonsteroidal antiinflammatory drugs (NSAIDs)
- Vitamin D
- Iron supplementation
Acetaminophen

- Stable liver disease without cirrhosis
  - Double-blind 2-period crossover study of 20 patients with chronic, stable liver disease (8 with cirrhosis) who tolerated acetaminophen (4g/day) for 13 days without adverse events
  - Based on limited data and possible adverse effects, most experts would limit to 2 g per day

- Cirrhosis
  - No prospective long-term studies of acetaminophen
  - Half-life of acetaminophen in patients with cirrhosis is double that in healthy controls
  - Based on limited data and possible adverse effects, most experts would limit to 1 g per day

NSAIDs

- Stable liver disease without cirrhosis
  - May be tolerated in mild chronic liver disease
- Cirrhosis
  - Greatest concerns are of associated renal impairment and hepatorenal syndrome
  - Also can cause mucosal bleeding secondary to thrombocytopenia and coagulopathy of advanced liver disease; greater risk in portal hypertension
  - Should be avoided in patients with cirrhosis

Vitamin Supplements: Vitamin D

- Vitamin D
  - May improve interferon alfa signaling and may have antiviral effects, deficiency may contribute to liver fibrosis

- Vitamin D in vivo effects
  - Vitamin D deficiency increases risk of bone disease, and advanced liver disease also increases risk of bone fracture
  - Cohort analyses demonstrate that low vitamin D levels are associated with nonresponse to interferon alfa–based therapy
  - Randomized trials of vitamin D supplementation in HCV genotype 1 patients treated with peginterferon alfa and ribavirin showed improved virologic responses
  - Results require further confirmation

- Recommendations
  - Vitamin D supplements to maintain 25-hydroxyvitamin D levels at or above 20 ng/mL, may require 2000 to 4000 IU per day of nutritional vitamin D

Vitamin Supplements: Iron (Fe)

- Excess Fe accumulation in the liver may occur in chronic liver disease
  - Up to 30% of those with hepatitis C virus (HCV) or alcoholic cirrhosis demonstrate serum accumulation of Fe; 10% with liver tissue deposition
- High hepatic Fe concentrations can be detrimental
  - Predictor of nonresponse to interferon alfa therapy
  - Animal (rat) studies: enhanced hepatotoxicity to alcohol when Fe coadministered
- Avoid excessive Fe in chronic liver disease
  - Choose multivitamin without Fe, unless Fe deficiency anemia is present
  - Dietary Fe not harmful

Alcohol and Cannabis
Alcohol

- Alcohol use
  - Associated with increased risk of cirrhosis, hepatocellular carcinoma, and mortality when greater than 48 g daily

- Alcohol use and HCV
  - Synergistic effect
  - Heavy alcohol use (> 50 g/day or > 5 drinks/day) associated with increased fibrosis
  - Light and moderate use also have an effect
    - Degree of fibrosis correlates with degree of use
    - Less than 31 g per day also exerted some effect on probability of increased fibrosis, with 31 g to 50 g per day exerting greater effect

Cannabis

- **Biologic effects**
  - Cannabinoid receptor types 1 and 2 regulate progression of experimental liver fibrosis

- **Use is associated with liver disease**
  - Daily cannabis use is associated with a higher risk of moderate to severe liver fibrosis
  - Combination of moderate to heavy alcohol use is associated with an even greater risk of fibrosis
  - Predictor of steatosis

- **Should be discouraged in those with chronic HCV**

Diet and Modifying Obesity
Diet and Modifying Obesity

- Obesity
  - Higher risk of advanced fibrosis with increasing obesity
- Elevated body mass index
  - Predictor of response to peginterferon alfa and ribavirin–based therapy
- Insulin resistance, without diabetes or obesity, is associated with treatment response, similar to HCV genotype
  - Insulin-sensitizing agents, including metformin or pioglitazone, have not improved HCV treatment outcomes

Diet and Modifying Obesity

- Weight loss (ideally 10%) and exercise may help

- Protease inhibitor use may mitigate the effects of insulin resistance on response
  - Baseline insulin resistance did not impact virologic response, in 1 telaprevir study

References:
Complementary and Alternative Medicines
Complementary and Alternative Medicines

- 42% of patients with chronic HCV use at least 1 herbal product
  - Milk thistle extract in 72%
  - Others commonly include S-adenosyl methionine (SAMe)
- Some herbal extracts associated with fulminant hepatitis

Complementary and Alternative Medicines

- Silymarin (milk thistle)
  - Animal model data suggest hepatoprotection during various liver insults
  - SyNCH trial (2012): double-blind, placebo-controlled
    - No change in serum ALT or HCV RNA during 24 weeks of silymarin
  - HALT-C study (2008)
    - No difference in anti-HCV efficacy or ALT but somewhat better quality of life

Complementary and Alternative Medicines

• SAMe
  o Has been shown to improve interferon alfa signaling
  o Supplementation improved early second-phase HCV viral kinetics, with modest improvement in SVR
  o Role in interferon alfa–sparing regimens unclear

Summary

- Over-the-counter and prescription medications
  - Limit acetaminophen to 2 g daily, 1 g daily in cases of cirrhosis
  - Avoid NSAIDs in cases of cirrhosis
  - Avoid Fe supplementation unless Fe-deficiency anemia present
- Alcohol and cannabis
  - Advise patients to avoid alcohol and marijuana
- Diet and modifying obesity
  - Obesity associated with increased risk of fibrosis
  - Weight loss and exercise recommended as adjunct to therapy
- Complementary and alternative medicines
  - Insufficient evidence to support their use
This presentation is brought to you by the International Antiviral Society-USA (IAS-USA) in collaboration with Hepatitis Web Study & the Hepatitis C Online Course

Funded by a grant from the Centers for Disease Control and Prevention